Improved Glycemic Control, Time in Target Range Found with iLet Bionic Pancreas

September 29, 2022 05:22pm

The iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.

September Month in Review: Top Stories on Drug Topics®
Increased Menstrual Cycle Length Tied to COVID-19 Vaccine
Efficacy and Safety of Ranibizumab and Lucentis for Wet AMD Compared
The Effects of Psychedelics in Healthy Participants